Table 2—

Prevalence of microvascular and macrovascular events

CH group (n = 131)
CN group (n = 39)
All subjects (n = 170)Odds ratio (95% CI)
MH group (n = 74)MN group (n = 57)Total (n = 131)MH group (n = 23)MN group (n = 16)Total (n = 39)
Medical events
 Nephropathy6903991054430.6 (0.3–1.1)
  Microalbuminuria6703252031321.0 (0.5–2.3)
  Clinical albuminuria120739024100.2 (0.1–0.7)*
 Retinopathy32182833624261.3 (0.5–2.9)
  Nonproliferative18915403126.4 (0.8–50)
  Preproliferative926130870.8 (0.2–3.1)
  Proliferative5871761380.5 (0.2–1.6)
 CHD811935020110.5 (0.2–1.3)
 CVD23111835021180.8 (0.3–1.9)
Medical treatment
 Therapy for hypertension
  Oral drugs61354870644471.2 (0.6–2.5)
 Therapy for diabetes
  Oral drugs or insulin9186891008895900.2 (0.0–1.5)
  • Data are %. The prevalence is a percent ratio of patients with MH, MN, CH, CN, or all patients. Odds ratio for CH and CN groups was calculated.

  • *

    * P < 0.01 versus patients with CN;

  • P < 0.01 versus patients with MN.